Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Carboplatin + Torkinib ovarian serous carcinoma not applicable detail...
Unknown unknown CFI-402257 ovarian serous carcinoma not applicable detail...
Unknown unknown Paclitaxel + Vistusertib ovarian serous carcinoma not applicable detail...
MAP2K1 Q56_V60del Selumetinib ovarian serous carcinoma predicted - sensitive detail...
BRAF V600E BGB-283 ovarian serous carcinoma predicted - sensitive detail...
Unknown unknown Berzosertib + Gemcitabine ovarian serous carcinoma not applicable detail...
BRAF V600E Trametinib ovarian serous carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02208375 Phase Ib/II Capivasertib + Olaparib Olaparib + Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Active, not recruiting USA 0
NCT02364713 Phase II Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting USA 0
NCT02446600 Phase III Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | CAN 2
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA 1
NCT02759588 Phase Ib/II GL-ONC1 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02898207 Phase I Olaparib + Onalespib Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT02983799 Phase II Olaparib Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Completed USA | CAN 0
NCT03042702 Phase II thioureidobutyronitrile A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer Completed USA 0
NCT03134638 Phase I Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 A Study of SY-1365 in Adult Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 1
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA 1
NCT03205176 Phase I AZD5153 Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting USA | CAN 0
NCT03402841 Phase III Olaparib Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION) Active, not recruiting CAN 17
NCT03414047 Phase II Prexasertib A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Active, not recruiting USA 7
NCT03462342 Phase II AZD6738 + Olaparib Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) Recruiting USA 0
NCT03531645 Phase II Fulvestrant + Palbociclib Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma Recruiting USA 0
NCT03587311 Phase II Anetumab ravtansine + Bevacizumab Bevacizumab + Paclitaxel Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting USA | CAN 0
NCT03602859 Phase III Dostarlimab + Niraparib Niraparib A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) Active, not recruiting USA | CAN 17
NCT03673124 Phase II Letrozole + Ribociclib Ribociclib and Letrozole Treatment in Ovarian Cancer Recruiting USA 0
NCT03695380 Phase I Atezolizumab + Cobimetinib + Niraparib Cobimetinib + Niraparib A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer Recruiting USA 3
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Active, not recruiting USA 4
NCT03909152 Phase II Onapristone A Study of Onapristone ER in Low Grade Serous Ovarian Cancer and Other Progesterone Receptor Positive Gynecologic Cancers Recruiting USA 0
NCT03955471 Phase II Dostarlimab + Niraparib Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE) Suspended USA 0
NCT04034927 Phase II Olaparib Olaparib + Tremelimumab Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Suspended USA 0
NCT04092270 Phase I MSC2490484A + Pegylated liposomal-doxorubicin A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients Recruiting USA 0
NCT04095364 Phase III Carboplatin + Letrozole + Paclitaxel Letrozole Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer Recruiting USA 1
NCT04209855 Phase III Paclitaxel Pegylated liposomal-doxorubicin Mirvetuximab Soravtansine Topotecan A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) Recruiting USA | CAN 10
NCT04293094 Phase I AMG 650 Study of AMG 650 in Adult Participants With Advanced Solid Tumors Recruiting USA | CAN 3
NCT04296890 Phase III Mirvetuximab Soravtansine A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (SORAYA) Recruiting USA 9
NCT04315233 Phase I Belinostat + Ribociclib Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) Recruiting USA 0
NCT04374630 Phase II Afuresertib + Paclitaxel Paclitaxel Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II) Recruiting USA 0
NCT04421963 Phase III Olaparib Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O) Recruiting USA | CAN 7
NCT04510584 Phase II Atezolizumab + Bevacizumab Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer Not yet recruiting CAN 0
NCT04586335 Phase I CYH33 + Olaparib Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Recruiting USA 1
NCT04625270 Phase II Defactinib + RO5126766 RO5126766 A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation Recruiting USA 0
NCT04669002 Phase II CRLX101 + Olaparib EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Recruiting USA 0
NCT04703920 Phase I Belinostat + Talazoparib Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Not yet recruiting USA 0